Logotype for Oryzon Genomics S.A.

Oryzon Genomics (ORY) investor relations material

Oryzon Genomics Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Oryzon Genomics S.A.
Q2 2025 earnings summary30 Jul, 2025

Executive summary

  • Secured €52M ($61M) in financing between Dec 2024 and July 2025, including a €30M capital raise, €7M in bank loans, €13.2M EU grant, and €1.8M R&D incentives.

  • Terminated convertible bonds facility with Nice & Green, increasing treasury stock to 2.37M shares.

  • Advanced clinical pipeline: Phase III protocol for vafidemstat in BPD submitted to FDA; expansion of schizophrenia trial; new autism aggression trial in preparation.

  • Significant progress in iadademstat oncology trials (AML, MDS, SCLC) and expansion into non-malignant hematological indications like sickle cell disease.

Financial highlights

  • R&D expenses: $3.0M (Q2 2025), $5.8M (H1 2025) vs $2.3M (Q2 2024), $4.9M (H1 2024).

  • G&A expenses: $1.4M (Q2 2025), $2.7M (H1 2025) vs $1.2M (Q2 2024), $2.1M (H1 2024).

  • Net loss: $1.7M (Q2 2025), $3.4M (H1 2025) vs $1.5M (Q2 2024), $2.6M (H1 2024).

  • Cash and equivalents: $36.5M as of June 30, 2025.

  • Total assets: $162.1M (June 2025) vs $118.5M (June 2024); equity: $133.9M (June 2025) vs $92.6M (June 2024).

Outlook and guidance

  • FDA approval for PORTICO-2 Phase III BPD trial expected in 2H25; trial to enroll 350 patients over 18 weeks.

  • New Phase II trial for vafidemstat in autism aggression to launch, supported by EU grant.

  • Expansion of schizophrenia trial into more EU countries to accelerate recruitment.

  • Anticipated data updates from iadademstat oncology trials at ASH-2025 conference.

  • CTA approval for iadademstat in sickle cell disease expected in September 2025.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Oryzon Genomics earnings date

Logotype for Oryzon Genomics S.A.
Q3 202523 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Oryzon Genomics earnings date

Logotype for Oryzon Genomics S.A.
Q3 202523 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Oryzon Genomics S.A. is a Spain-based clinical-stage biopharmaceutical company focused on the discovery and development of epigenetic therapies. The company develops small molecule inhibitors targeting specific enzymes involved in gene expression regulation, with therapeutic programs in oncology and neurodegenerative diseases. Oryzon conducts both preclinical and clinical trials and collaborates with academic and industry partners to advance its drug candidates. The company is headquartered in Barcelona, Spain, and its shares are listed on the BME.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage